Spero Therapeutics (NASDAQ:SPRO) Raised to “Hold” at Zacks Research

Spero Therapeutics (NASDAQ:SPRO) was upgraded by research analysts at Zacks Research to a “hold” rating in a report issued on Monday, Zacks reports.

SPRO has been the topic of several other reports. Compass Point upgraded Spero Therapeutics to a “neutral” rating in a research report on Monday. Weiss Ratings upgraded Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 12th. Finally, HC Wainwright upped their target price on Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Spero Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Spero Therapeutics Stock Performance

Shares of NASDAQ:SPRO opened at $1.13 on Monday. Spero Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.08. The firm has a fifty day moving average of $1.32 and a 200 day moving average of $2.10. The firm has a market capitalization of $65.81 million, a PE ratio of 10.27 and a beta of 1.49.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. On average, sell-side analysts forecast that Spero Therapeutics will post -0.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna Fundamental Investments LLC purchased a new position in shares of Spero Therapeutics in the second quarter worth about $36,000. Global Retirement Partners LLC purchased a new stake in Spero Therapeutics during the 2nd quarter valued at about $55,000. Intrepid Family Office LLC boosted its holdings in Spero Therapeutics by 50.0% during the 4th quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock valued at $384,000 after acquiring an additional 55,000 shares during the period. GSA Capital Partners LLP bought a new position in Spero Therapeutics during the 2nd quarter worth approximately $632,000. Finally, BlackRock Inc. bought a new position in Spero Therapeutics during the 2nd quarter worth approximately $1,314,000. 25.60% of the stock is owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.